Key Highlights

  • Third-quarter Revenue grew 129% to USD 244,034.
  • Specimen count climbed 169% to 752 from 280.
  • Net loss narrowed 20% to USD 2.2 million.
  • Cash stood at USD 5.6 million at September 30.

More specimens sold at lower prices produced the revenue gain at iSpecimen (NASDAQ:ISPC). Third-quarter 2026 revenue was USD 244,034 versus USD 106,592, an increase of 129%. Specimen count rose about 169%, to 752 from 280, a rise the company ascribes to more customer orders and more procurement. Meanwhile the average selling price per specimen eased about 15%, to roughly USD 325 from USD 381.

Over nine months, however, revenue remains lower than a year ago. Incorporated in Delaware in 2009, the company runs its own online marketplace where medical researchers can reach hospitals, laboratories and other holders of biospecimens, among them biofluids, tissues and living cells.

Costs and the Loss

Total operating expenses fell 17% to USD 2,441,243 from USD 2,936,814, and the loss from operations narrowed 22% to USD 2,197,209. The net loss was USD 2,211,994 versus USD 2,780,648, or USD 1.03 per share versus USD 19.05. No estimates existed for the period.

Cost of revenue dropped 55% to USD 91,156, helped by an 83% fall in the average cost per specimen. Technology expense declined 48% to USD 286,543, chiefly because less internally developed software was being amortized, and roughly USD 700,000 of technology spending moved onto the Balance Sheet as software after a platform milestone was reached.

Sales and Marketing rose 21% to USD 1,379,947 on Advertising and promotion. General and administrative expense fell 37% to USD 547,984 and fulfillment fell 30% to USD 106,977. Other income, net, was down 74% in the quarter to USD 12,442. Supply development expense rose 28% to USD 28,636, and interest expense was USD 27,500 versus USD 2 a year earlier.

Nine Months and Cash

Revenue for nine months was USD 551,983 versus USD 1,877,237, a 71% decrease. Operating expenses fell 19% to USD 6,650,580. The loss from operations was USD 6,098,597 versus USD 6,290,037, an improvement of 3%, while the net loss was USD 5,850,026 versus USD 5,486,287, up 7%. Loss per share was USD 4.49 versus USD 61.54.

Over the period, sales and marketing costs climbed sharply on advertising and promotion, professional fees dropped, and compensation within general and administrative expense declined by about USD 123,000.

Cash and cash equivalents fell 19% to USD 5,556,914 from USD 6,880,835, whereas total Assets rose 2%, from USD 9,531,410 to USD 9,700,831. These figures cover the three and nine months to September 30, 2026.

Points to follow are whether higher specimen volumes last, how pricing per specimen holds, how much is spent on advertising and promotion and how quickly the USD 5.6 million balance is drawn down.